Eli Lilly: BofA Global Research raises price objective to $1,557 from $1,497
LLY•BofA Global Research raised its price objective on Eli Lilly to $1,557 from $1,497.
Related News
BofA Global Research raises Revolution Medicines price objective to $274 from $264
RVMD•
ProFrac Q3 2026 net loss narrows 20% to $74 million; revenue rises 27% to $511.1 million
ACDC•
Duke Energy Q3 2026 adjusted EPS rises 10% to $1.99
DUK•
Lincoln National Q3 adjusted EPS misses estimates
LNC•
Trulieve swings to Q3 net profit of $800,000 year over year
TCNNF•